Day: March 2, 2022

CICERO, Ill., March 02, 2022 (GLOBE NEWSWIRE) — Broadwind (NASDAQ: BWEN, or the “Company”), a diversified precision manufacturer of specialized components and solutions serving global markets, today announced results for the fourth quarter and full-year 2021. FULL-YEAR 2021 RESULTS(As compared to the full-year 2020)Total revenue of $145.6 million, (27%) y/y Total gross profit of $5.5 million, (69%) y/y Total non-GAAP adjusted EBITDA of $13.2 million, +65% y/yFOURTH QUARTER 2021 RESULTS(As compared to the fourth quarter 2020)Total revenue of $26.0 million, (35%) y/y Total gross profit of $1.0 million, (64%) y/y Total net loss of ($4.1) million, or ($0.21) per basic share Total non-GAAP adjusted EBITDA of ($1.2) million Total cash and excess availability of $14.9 millionFor the three months ended December 31, 2021, the Company...

2021 revenue increased 66% over prior year period BRANFORD, Conn., March 02, 2022 (GLOBE NEWSWIRE) — IsoPlexis Corporation (Nasdaq: ISO), the Superhuman Cell Company, today reported financial results for the quarter and year ended December 31, 2021. Recent HighlightsRevenue of $5.5 million for the fourth quarter and $17.3 million for the full year 2021, representing 63% and 66% increases, respectively, over the corresponding periods of 2020 Sold 98 new instruments in 2021, bringing the installed base to 209 total instruments Released The Superhuman Cell Library, an industry-first mapping of the proteomically driven cells that determine how the human body responds to complex disease Presented new data generated on the IsoLight highlighting how to leverage “superhero” cells for optimization of CAR-T manufacturing as well as clinical...

Worldwide Ocaliva® net sales of $92.4 million and $363.5 million for the fourth quarter and full year 2021, representing 11% and 16% growth over the prior year Company provides 2022 Ocaliva net sales guidance of $375 million to $405 million and non-GAAP adjusted operating expense guidance of $360 million to $390 million Data package from REGENERATE Phase 3 study in fibrosis due to NASH being generated; targeting potential pre-submission meeting with FDA in 1H 2022 Topline results from REVERSE Phase 3 study in compensated cirrhosis due to NASH now expected in Q3 Company to host conference call today at 8:30 a.m. ET NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral...

DENVER, March 02, 2022 (GLOBE NEWSWIRE) — TrackX Holdings Inc. (TSX.V:TKX | FRANKFURT:3TH) (“TrackX” or the “Company), a Software-as-a-Service (SaaS)-based enterprise asset management solution provider, announces the financial and operational highlights from its first quarter ended December 31, 2021 (“Q1, 2022”). All results are reported in Canadian dollars unless otherwise specified. A complete set of the September 30, 2021 Consolidated Financial Statements and Management’s Discussion & Analysis has been filed on SEDAR (www.sedar.com). During the three months ending December 31, 2021 (“Q1, 2022”), the Company continued to invest and focus on its strategy of delivering its enterprise scalable, IoT-enabled technology platform in response to increased demand by companies for better supply chain tracing, tracking, execution,...

 Operating income for the year increased 26.2% year over year to a record breaking $51.2 million; Non-GAAP operating income for the year increased 27% year over year to a record-breaking $66.8 million Or Yehuda, Israel, March 02, 2022 (GLOBE NEWSWIRE) — Magic Software Enterprises Ltd. (NASDAQ and TASE: MGIC), a global provider of IT consulting services and end-to-end integration and application development platforms solutions, announced today its financial results for the fourth quarter and full year ended December 31, 2021. Summary Results for the Fourth Quarter 2021 (USD in millions, except per share data)    GAAP           Non-GAAP            Q4 2021     Q4 2020     % Change     Q4 2021     Q4 2020     % Change  Revenues   $ 133.0     $ 104.6       27.2 %   $ 133.0     $ 104.6       27.2 %Gross Profit   $ 37.4     $ 30.9       21.0 %   $ 38.7     $ 32.5       19.2 %Gross...